| Date | Title | Description |
| 03.04.2025 | Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline | South San Francisco, CA, April 3, 2025 – Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion o... |
| 06.12.2024 | Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society | San Francisco, CA, December 6, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for epilepsy and other disorders of the nervous system, today announced positive clinical data from t... |
| 10.09.2024 | Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate | SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that the California Institute for Re... |
| 12.03.2024 | Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days | SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced that Cory R. Nichol... |
| 12.03.2024 | Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days | - |
| 07.03.2024 | Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001 | - |
| 09.02.2024 | Neurona Therapeutics Raises $120M in Funding | Neurona Therapeutics, a San Francisco, CA-based clinical-stage biotherapeutics company, raised $120M in funding.
The round was led by Viking Global Investors and Cormorant Asset Management with participation from new and existing investors,... |
| 08.02.2024 | Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders | San Francisco, CA, February 8, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of a ... |
| 08.02.2024 | Neurona Therapeutics Lands $120M |
SAN FRANCISCO, CA, Neurona Therapeutics today announced the successful completion of a $120 million financing.
>> Click here for more funding data on Neurona Therapeutics
>> To export Neurona Therapeutics funding data to PDF... |
| 08.02.2024 | Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders | - |
| 08.02.2024 | Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders | The financing, co-led by Viking Global Investors and Cormorant Asset Management with participation from The Column Group along with additional new and existing investors, follows promising early clinical data from NRTX-1001 epilepsy program... |
| 08.02.2024 | Don't call it a comeback, but Neurona knocks out $120M raise a year after layoffs | Almost a year ago to the day, Neurona Therapeutics was cutting staff, citing a difficult funding environment. Fast forward to today, and the company has reeled in a much-needed $120 million. But according to CEO Cory Nicholas, Ph.D., you de... |
| 16.05.2022 | Meet Richard Chan, Managing Partner at Berkeley Frontier Fund | Richard Chan, Managing Partner at Berkeley Frontier Fund Richard Chan is a serial entrepreneur and
Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While... |
| 13.10.2021 | Digital health news, funding roundup in the prior week; October 11 | CVS Health turning drugstores into super-clinics; BetterUp raises another round for $5B valuation
Headlines from last week:
A number of 2021 healthtech companies are trading below their IPO price, with reduced market caps. More healthtech c... |
| 07.10.2021 | Daily funding roundup - October 7, 2021 | Neumora Therapeutics raised $500M; Solo.io landed $135M; Lightship secured $40M
Neumora Therapeutics: Neumora Therapeutics is a Watertown, Ma.-based developer of precision medicines for brain diseases. Neumora Therapeutics has raised $500 m... |
| 22.06.2021 | Neurona Therapeutics Secures $41.5M |
SAN FRANCISCO, CA, Neurona Therapeutics today announced the successful completion of a $41.5 million financing.
>> Click here for more funding data on Neurona Therapeutics
>> To export Neurona Therapeutics funding data to PD... |
| 22.06.2021 | Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders | Syndicate includes premier healthcare investors steeped in neurology
Erica Whittaker, Ph.D., head of UCB Ventures, joins
Neurona’s board of directors
Latest financing brings total proceeds raised to date to $135 million
SAN FRANCISCO, June ... |
| 02.12.2015 | Daily funding roundup - December 2, 2015 | ORIC Pharmaceuticals bagged $53M; Bluecore raised $21M; Osaro announced $3.3M funding
Technology innovators Realsafe Technologies have secured £1 million (approximately $1.5 million) of investment to scale their business, bringing with it n... |
| 02.12.2015 | Neurona gets $23.5M for stem cell approach to neurological disease | The idea, says interim CEO Tim Kutzkey, is to create novel therapeutics that permanently repair dysfunctional neural circuits. After all, UCSF researchers have found in animal models that certain neuron transplants can rebalance nervous sys... |
| 01.12.2015 | Neurona Therapeutics Raises $23.5M in Series A Financing | Neurona Therapeutics Inc., a South San Francisco, CA-based biotechnology company focused on the transplantation of selected neurons to treat intractable neurological diseases, launched with a $23.5m Series A financing.
The round was led by ... |
| 24.12.2014 | Stem cells to transplant in the brain: Stealth UCSF spinout Neurona Therapeutics raises $7.6M | Also listed is Leo Guthart, a managing partner at New York private equity firm TopSpin Partner, and Arnold Kriegstein, director of the UCSF developmental and stem cell biology program.
Kriegstein and his UCSF colleagues filed a patent for t... |
| - | Stem cells to transplant in the brain: Stealth UCSF spinout Neurona Therapeutics raises $7.6M | A UCSF spinout is growing neuronal stem cells to transplant into the brain, for potential use in treating epilepsy, spinal cord injury, Parkinson’s and Alzheimer’s disease – and investors are listening. Because one thing that differentiates... |
| - | Neurona Therapeutics | “Neurona is developing cell therapies for targeted repair of dysfunctional neural circuits underlying chronic diseases” |
| - | Neurona gets $23.5M for stem cell approach to neurological disease | UCSF spinout Neurona Therapeutics has closed out a $23.5 million Series A round for its technology that allows neuron transplantation to treat neurological diseases.
This stem cell company closed out the first tranche of the round one year ... |
